Clinical Trials Browser

Hematologic Neoplasms × pirtobrutinib × Clear all

NCT05529069 2026-05-05

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Lymphoma, Mantle-Cell